Skip to main content

Immucell Corp

ICCC
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0000811641

No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Immucell Corp changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of ICCC: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders26127+2
Shares1.28M303.0K1.37M+392.2K (+40.2%)
Value$7.87M$1.86M$8.67M+$2.66M (+44.2%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Immucell Corp at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ICCC in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Capital Management LLC260,327$1.65M0.00%
Vanguard Fiduciary Trust Co42,669$270.1K0.00%
Militia Capital Management LLC18,000$113.9K0.03%
Bailard, Inc.10,102$63.9K0.00%
Advisory Services Network, LLC200$1.27K0.00%

Sold out (3)

Institutions that held Immucell Corp at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of ICCC in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Dauntless Investment Group, LLC39,633$243.7K
Bank of America Corp2,040$12.5K
Flagship Harbor Advisors, LLC730$4.49K

Not filed for Q1 2026 yet (1)

Institutions that held Immucell Corp at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ICCC in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc302,996$1.86M